GRAPPA Evidence-Based Treatment Guidelines for Psoriatic Arthritis. Peripheral joint disease Dr. Enrique R. Soriano Dr. Neil J. McHugh.

Slides:



Advertisements
Similar presentations
Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.
Advertisements

NSAIDs 1 st line of therapy in the medical management of RA.
Ankylosing spondylitis
Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
Drug Therapy for Rheumatoid Arthritis in Adults Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
1 Abatacept Brian Daniels, M.D. Senior Vice-President Global Clinical Development Bristol-Myers Squibb.
Psoriatic Arthritis: Creating a Model for Cost- Effectiveness Analysis GRAPPA meeting San Antonio, TX October 15, 2004 Supported by Schering Participants:
Guidelines for Care Needs a team approach of rheumatologists, dermatologists and patients (NPF, ?AF) Combination of Cost and Evidence Based Criteria will.
Guidelines Mission Statement “To develop guidelines, based upon the best scientific evidence, for the optimal treatment of patients with psoriatic arthritis.
Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
IL-6 Inhibition in RA An Emerging Role for Tocilizumab HIGHLIGHTS FROM EULAR 2008 PRESENTATIONS.
Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid.
Methods to Analyse The Economic Benefits of a Pharmacogenetic (PGt) Test to Predict Response to Biologic Therapy in Rheumatoid Arthritis, and to Prioritise.
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
DR.IBTISAM JALI MEDICAL DEMONSTRATOR
Arthritis Advisory Committee March 5, 2003 Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory, Ophthalmologic Drug Products HFD-550/CDER/FDA.
Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.
New Pharmacologic Treatment Options for Managing Rheumatoid Arthritis Devra Dang, Pharm.D. Department of Pharmacy National Institutes of Health.
GRAPPA Guidelines for PsA: Considerations
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.
How to Analyze Systematic Reviews: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
Arthritis Advisory Committee August 16, 2001
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
QOL/Function/Participation Committee Projects to be done –Validation of current measures: HAQ, SF- 36, DLQI, PsAQOL –Development of MCID – need to validate.
NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.
EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.
Objectives  Identify the key elements of a good randomised controlled study  To clarify the process of meta analysis and developing a systematic review.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Dr. M Jokar RA - Definition u Chronic systemic inflammatory disorder u Unknown etiology u Synovium affected u Joint Deformity u Extra-articular.
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
Dr.B.V.Venkataraman Professor in Pharmacology International Medical School Faculti Perubatan, New BEL Rd Bangalore Drugs.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Guideline Development Societal needs have driven guideline development to the forefront: – Aid physician education on new clinical information – Set research.
OUTCOME MEASURES IN PsA: IMMUNOHISTOLOGY Oliver FitzGerald.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.
ViscosupplementationViscosupplementation for arthritis of the knee.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Rheumatoid Arthritis: Management and New Therapies
Eucrisa™ - Crisaborole
From: Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled TreatmentA Randomized Trial Ann Intern Med.
Neal B, et al. Diabetes Care 2015;38:403–411
Psoriatic Arthritis.
Clinical Developments in Inflammatory Arthritis 2017
Posters & Abstracts from Amsterdam
Pearls Presentation Use of N-Acetylcysteine For prophylaxis of Radiocontrast Nephrotoxicity.
Evolving Treatment Landscape for PsA
Biotherapeutics.
The American College of Cardiology Presented by Dr. Timothy Henry
Presentation data from US VICTORY Consortium
Rheumatoid Arthritis.
Kelly Schatzlein PA-S and Keely Tietjen PA-S
Treatment Advances for RA
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Presentation transcript:

GRAPPA Evidence-Based Treatment Guidelines for Psoriatic Arthritis. Peripheral joint disease Dr. Enrique R. Soriano Dr. Neil J. McHugh

Peripheral joint disease Objective: present the best scientific evidence as it relates to the treatment of peripheral joint involvement in PsA. Literature search included: – EBD: Medline, Embase, Ovid, and Lilacs back to 1966; and – SRD: Cochrane (CDSR; CCTR) – Manual search of references – Recently published BSR guideline for anti-TNF alpha therapy in PsA (: Key words: psoriatic arthritis, psoriasis treatment, and each one of the treatments and psoriasis and/ or psoriatic arthritis

Categories of evidence: AHCPR Evidence 1A Meta-analysis of RCT 1B One or more RCT 2A One or more CT 2B well designed studies 3 non experimental studies 4 Expert opinions, clinical experience Grade A Grade B Grade C Grade D Recommendation

What is the evidence regarding efficacy of NSAIDs, systemic steroids and intraarticular steroids in treating peripheral arthritis of PsA?" NSAIDs: evidence grade 1B for : (recommendation grade A) indomethacin, diclofenac, azapropazone, acemetacin and ibuprofen to improve symptoms in PsA. (Nimesulide not recommended) There is lack of sufficient data to support recommendations for the use of Cox-2 specific NSAIDs in psoriatic arthritis. There have been reports of exacerbations of psoriasis with NSAIDs, (evidence grade 4). Systemic corticosteroids: Evidence grade 4, recommendation grade D. Intraarticular corticosteroids: Evidence grade 4, (evidence grade 3?) recommendation grade D (recommendation grade C?).

What is the evidence regarding efficacy of DMARDs on symptom improvement on peripheral arthritis of PsA? Methotrexate: Only parenteral methotrexate at a unacceptably high toxic dose has well demonstrated published efficacy Data for oral MTX suggest it may be beneficial but conclusive proof of its efficacy is still lacking. (evidence grade 2B) Sulphasalazine: Evidence grade 1A Cyclosporine: Evidence grade 1B Leflunamide: Evidence grade 1B efficacy for symptom control and improving functional status and quality of life

What is the evidence regarding efficacy of DMARDs on symptom improvement on peripheral arthritis of PsA? Gold (Oral, IM): Evidence grade 1A, that intramuscular or oral gold are no better than placebo Azathioprine: Not well demonstrated published efficacy. The magnitude of the effect seen in one RCT suggests that it may be effective. Antimalarials: Evidence grade 3

What is the evidence regarding DMARDs on radiogrpaphic progression on peripheral arthritis of PsA? Methotrexate: Evidence grade 3 MTX does not prevent radiographic progression Sulphasalazine: Evidence grade 3 that SSZ does not prevent radiographic progression Cyclosporine: Evidence grade 3 that CyA is able to control radiographic progression defined as the development of less than two new eroded joints Leflunamide: Evidence grade 4 that leflunomide might prevent radiographic progression Gold (Oral, IM): Evidence grade 3 IM Gold does not prevent radiographic progression

What is the evidence regarding DMARDs toxicity on patients treated for PsA? Methotrexate: Liver toxicity: more likely in PsA than in RA (evidence 2B) Histopathologic changes not predicted by abnormal LFT (evidence 2B). The risk of liver fibrosis: related to methotrexate cumulative dose. Progression to clinically significant cirrhosis: uncertain and may be low (evidence 2B). Liver biopsy considered in patients exceeding 1.5g of cumulative dose of methotrexate (evidence 2B, recommendation grade B). Evidence grade 3 that serial evaluations of amino-terminal propeptide of type III procollagen levels are useful for selecting patients for liver re-biopsies Sulphasalazine: There is a high withdrawal rate in patients due to adverse events. (evidence grade 3). Cyclosporine: less well tolerated than other DMARDs (evidence grade 3), significant renal toxicity (evidence grade 2B). Close monitoring of patient’s blood pressure and renal function should be done before and during treatment (recommendation grade B).

What is the evidence regarding DMARDs toxicity on patients treated for PsA? Leflunamide: Diarrhea and elevated ALT levels: higher frequencies in patients treated with leflunomide compared with placebo (evidence grade 1B). Long term data from patients with PsA treated with leflunomide are not yet available. Gold (Oral, IM): Gold is well tolerated in most patients with PsA. Follow up studies showed lower treatment survival rate with gold than with other DMARDs. (evidence grade 3) Antimalarials: Evidence grade 3 that they may exacerbate psoriasis.

Anti TNF alpha Therapy. Etanercept Two controlled randomized trirals (60 and 205 patients). Summary: Efficacy. Toxicity There is evidence grade 1B, that etanercept has efficacy in symptom, disability and quality of life improvement in PsA patients. There is evidence grade 1B that etanercept is able to control radiographic progression in the short term in PsA There is evidence grade 1B, that etanercept is safe in the short term in patients with PsA

Anti TNF alpha Therapy. Infliximab A randomized, double blind trial of infliximab, 5 mg/Kg, or placebo (102 patients) Summary: Efficacy. Toxicity There is evidence grade 1B, that infliximab has efficacy in symptom improvement in PsA patients. There is no evidence that infliximab stop radiographic progression There is evidence grade 1B that infliximab is safe in the short term in patients with PsA

SSZMTXCyALFNOGIMGAZAEtanarcept Combe 1996 *Gupta 1995 Clegg 1996 Willkens 1984 Salvarani 2001 Kaltwass er 2004 Carrete 1989 Palit 1990 Levy 1972 Mease 2000 n patients 117; * Weeks follow up 24;* Tender joint score 0,160,120,060,440,650,220,782,682,29 & Swollen Joint score 0,18*0,02 0,46 #0,17 0,33 --1,32# Pain (VAS) 0, ,533,640,03 - Cohen´s d effect size calculated on mean changes between baseline and final visit of selected outcomes variables for different DMARDs. medium effect (>=.40 and =.75 and <1.10); very large effect (>=1.10 and 1.45

SSZMTXCyALFNOGIMGAZAETNINF Evidence symptom control 1A2B1B -1A 2B1B Effect size SENEMELESE HE - Evidence x-Ray B- ToxicityLow High ? LowMed LowLow ? Recomm. Grade? A- B? B- C ? A-B?A-A BAA -: Means evidence against. NE: negligible effect;SE: Small effect; ME: Medium effect ; LE: Large effect; HE: Huge effect Strength of Recommendation:Level evidence; Effect size, side effect profile

Should all patients with PsA receive DMARDs? There is evidence grade 2A that psoriatic arthritis is a progressive disease that can inflict severe damage. Clinical subgroups appears to change over time and the mode of onset does not predict outcome (evidence grade 2B). Patients with a higher number of inflamed joints are at greater risk of progressive damage (evidence grade 2B). There is no evidence other than expert opinion that early aggressive treatment can prevent disease progression (evidence grade 4)

THANK YOU